Immunocore Holdings (IMCR) Cash from Investing Activities (2021 - 2026)

Immunocore Holdings (IMCR) has reported Cash from Investing Activities for 6 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Investing Activities fell 56.51% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.8 million (up 93.67% YoY) and the FY2025 annual result came in at -$16.3 million, up 95.4% from the prior year.
• Cash from Investing Activities grew to $4.2 million in Q1 2026 per IMCR's latest filing, from -$880000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for IMCR reached as high as $9.7 million in Q1 2025 and fell as low as -$350.3 million in Q2 2024.
• A 5-year average of -$24.8 million and a median of -$817000.0 in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 25013.33% — and 2025, when it surged 2356.28%.
• Year by year, Cash from Investing Activities stood at $389412.2 in 2022, then sank by 309.8% to -$817000.0 in 2023, then slumped by 333.29% to -$3.5 million in 2024, then surged by 75.14% to -$880000.0 in 2025, then surged by 579.43% to $4.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $4.2 million, -$880000.0, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.